Acadia Pharmaceuticals ACAD Q3 2026: DAYBUE Surges 39%, Guidance Raised

As seen on the 24/7 Wall St. homepage on November 4, 2026.

ACAD Acadia Pharmaceuticals
Q3 2026
EPS
$0.31
est $0.18 +69.9%
Revenue
$342M
est $333M +2.9%

DAYBUE net sales jumped 39% to $140.1 million on STIX uptake, enough for management to raise full-year guidance for the drug to $505 million to $520 million. Both franchises beat expectations.

Continue ReadingShow less

Acadia Pharmaceuticals posted Q3 2026 earnings per share of $0.31 on a GAAP basis, nearly 70% above the consensus estimate of $0.18. That beat landed even as the quarter absorbed $26.9 million in income tax expense, a sharp reversal from the $27.2 million tax benefit the company recorded in the same period a year ago. Revenue of $342.3 million cleared the $332.6 million analyst estimate by about 2.9% and rose roughly 23% year over year.

The standout driver was DAYBUE, Acadia's treatment for Rett syndrome, whose net sales jumped 39% to $140.1 million. Management credited meaningful uptake of the DAYBUE STIX formulation for the acceleration. NUPLAZID, the company's Parkinson's disease psychosis franchise, contributed $202.2 million, up 14%, supported by underlying demand and an expanded commercial footprint.

Income from operations roughly doubled year over year to $71.7 million, helped in part by lower R&D spending, which came in at $76.3 million versus $87.8 million in the prior-year quarter. Net income of $53.5 million was down about 25% year over year, a reflection of that unfavorable tax swing rather than any deterioration in operating performance.

Sponsored

On the strength of the quarter, management raised its full-year DAYBUE global net sales guidance to $505 million to $520 million, up from the prior range of $480 million to $510 million. Total revenue guidance was tightened to $1.265 billion to $1.295 billion, while the R&D expense outlook was cut to $325 million to $340 million from $355 million to $380 million, signaling growing confidence in the company's ability to convert commercial momentum into earnings.

Looking further out, Acadia is pursuing two Phase 2 readouts in 2027: ACP-211 in major depressive disorder in the second half of the year, and remlifanserin in Lewy body dementia psychosis in the fourth quarter, the first time the company has provided timing guidance on the latter. Remlifanserin has received FDA Fast Track designation for Lewy body dementia psychosis, and additional Phase 2 data from the RADIANT Alzheimer's disease psychosis study are set to be presented at a medical conference on November 17, 2026. A regulatory filing for trofinetide in Japan is planned for 2027, with a potential launch in 2028.

Mentioned: ACAD